SABS compared with ANRO: revenue, margins and what each company keeps, and the suppliers and customers both name

SABSSAB Biotherapeutics, Inc.

Mkt capRevenueRevenue

ANROAlto Neuroscience, Inc.

Mkt capRevenueRevenue

Compare

SABSSAB Biotherapeutics, Inc.

ANROAlto Neuroscience, Inc.

Price

Mkt cap

Revenue

Earnings history

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

last 4 reports each · paired by recencyMethod ›

SABS

No earnings history for SABS.

ANRO1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±13.6%▲+10.69%×0.79

= impliedSABS realized, solidANRO realized, hatchedOne scale, both sides: full bar = 14%× = |realized| ÷ impliedSource: market data

SABSSAB Biotherapeutics, Inc.

3.34▲+3.39%· post 3.34

Mkt cap$304.8MRevenue$114,698Q4 FY24

ANROAlto Neuroscience, Inc.

22.40▼−4.56%· post 22.40

ClosedOct 30 '26

Mkt cap$886.9MRevenue—

Compare

ClosedOct 30 '26

SABSSAB Biotherapeutics, Inc.

ANROAlto Neuroscience, Inc.

3.34▲+3.39%post 3.34

Price

22.40▼−4.56%post 22.40

$304.8M

Mkt cap

$886.9M

Q4 FY24$114,698

Revenue

—

SABS3.34▲+3.39%vsANRO22.40▼−4.56%ClosedOct 30 '26